Award given for saving millions of lives by providing sustained access to childhood vaccines around the globe

Geneva, 10 September 2019 – The Albert and Mary Lasker Foundation announced today that Gavi, the Vaccine Alliance has received the prestigious 2019 Lasker~Bloomberg Public Service Award for providing sustained access to childhood vaccines in the world’s poorest countries, saving millions of lives and highlighting the power of immunisation to prevent diseases.

“It is a great honour for us to receive such a prestigious Award,” said Dr Seth Berkley, CEO of Gavi the Vaccine Alliance. “Since its creation in 2000 at Davos, Gavi has been making it possible for the world’s most vulnerable children to receive the vaccines they need to live healthy, successful lives. Our collective work as an Alliance has prevented more than 13 million deaths in developing countries while child mortality was halved largely thanks to immunisation. I couldn’t be prouder of what we have accomplished together.”

Our collective work as an Alliance has prevented more than 13 million deaths in developing countries while child mortality was halved largely thanks to immunisation. I couldn’t be prouder of what we have accomplished together. 

Dr Seth Berkley

Gavi CEO

Gavi now helps immunise around half the world’s children through a unique public-private partnership that brings together governments, private donors, industry, civil society organisations and international organisations to deliver life-saving vaccination programmes in low-income countries. Driven by country leadership, Gavi offers vaccines at a lower cost while countries take a share of costs and build sustainable immunisation programme before transitioning out of Gavi support.

“On behalf of the hundreds of thousands of vaccinators, health workers and partners that make up our Vaccine Alliance, we are delighted to receive the Lasker~Bloomberg Public Service Award,” said Dr Ngozi Okonjo-Iweala, Chair of the Gavi Board. “All children – regardless of whether they are girls or boys, where they live or how poor they are – have the right to be protected against deadly diseases. However, nearly 20 million children are still missing out on a full course of the most basic vaccines, and more than 10 million do not even receive the first dose. Building on nearly two decades of steady progress, Gavi will redouble efforts in the coming years to extend immunisation services to those communities missed today.”

On behalf of the hundreds of thousands of vaccinators, health workers and partners that make up our Vaccine Alliance, we are delighted to receive the Lasker~Bloomberg Public Service Award.

Dr Ngozi Okonjo-Iweala

Chair of the Gavi Board

Every year since 1945, the Lasker Foundation has presented a range of awards for some of the most accomplished people and institutions involved in breakthrough biological discoveries and clinical health advances. The Lasker~Bloomberg Public Service Award honours exceptional individuals or organisations whose impact on public health or public service has enlarged the possibilities for medical research and the health sciences.

The Lasker Foundation will formally present the Public Service Award to Gavi, the Vaccine Alliance at a ceremony on September 20 in New York City.

Since 2000, Gavi has supported more than 460 vaccine introductions and campaigns, providing funding for vaccine procurement and strengthening health systems. Gavi also funds the global stockpiles of cholera, yellow fever and meningitis vaccines, and supports measles response. Gavi stimulates the dissemination of new vaccines such as the Ebola vaccine that is now being used in the Democratic Republic of the Congo. Gavi is funded through contributions by governments as well as Foundations and the private sector.

The Alliance recently unveiled in Japan its 2021-25 Investment Opportunity calling on donors to back plans to immunise an additional 300 million children in developing countries against deadly diseases, saving a further seven to eight million lives. The replenishment process will culminate in a special event hosted by the UK government, mid-2020.


Notes to editors

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 760 million children – and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and Twitter.

The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.

Latest news

View all

8 December 2022

Gavi Board Decisions Outline “Year of Renewal” for Vaccine Alliance

Board underlines commitment to end backsliding in routine immunisation, catching up coverage and reaching zero-dose children as the Vaccine Alliance’s core priorities for the remainder of the current 2020–2025 strategic period.

3 November 2022

Global health agencies outline plan to support Ugandan government-led response to outbreak of Ebola virus disease

3 November 2022 – Following the declaration of an Ebola outbreak in Uganda on 20 September 2022, the outbreak has now spread to seven districts (Kasanda, Kyegegwa, Bunyangabu and Kagadi districts beyond the original epicenter in Mubende district…

3 November 2022

Gavi sets course to support sustainable vaccine manufacturing in Africa with new action plan in support of the African Union’s 2040 vision

Gavi publishes plan of action to support the development of sustainable vaccine manufacturing in Africa.

28 October 2022

Lower-income countries push to reach more than 85 million children with measles vaccine

Following an alarming global rise in measles cases and outbreaks, lower Income countries are accelerating efforts with support from Gavi, the Vaccine Alliance.

17 October 2022

Gavi, Moderna update COVAX supply agreement; agree on access to variant-containing vaccines for lower-income countries

Gavi and Moderna agree to cancel remaining volumes under existing COVAX supply agreement.

3 October 2022

Sierra Leone introduces HPV vaccine to protect girls from cervical cancer

In a move to protect adolescent girls from cervical cancer, the Government of Sierra Leone today introduced the Human Papilloma Virus (HPV) vaccine to the routine immunisation schedule and launched the start of a campaign to reach 153,991 girls…

29 September 2022

Amid challenges, signs of recovery in routine immunisation as countries administer record volumes of vaccines in 2021

Routine immunisation coverage fell for a second consecutive year in 2021 across 57 Gavi-supported countries, although preliminary data shows signs of improvement in early 2022.

9 September 2022

Gavi Vaccine Investment Strategy Steering Committee is now open for applications

The VIS Steering Committee will be convened to provide expert advice across multiple perspectives and deliberations and will provide technical input into the development of Gavi Secretariat’s recommendations to the Programme and Policy Committee…

5 September 2022

Call for Applications: COVAX seeks experts for independent group on evidence-based vaccine decision-making

The COVAX Facility is seeking expressions of interest from the subject matter experts to join the COVAX Independent Product Group. The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and make…

Subscribe to our newsletter